Global Tuvonralimab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Tuvonralimab market size was valued at US$ 82.32 million in 2025 and is forecast to a readjusted size of US$ 461 million by 2032 with a CAGR of 10.4% during review period.
Tuvonralimab is a recombinant humanized monoclonal antibody that selectively targets cytotoxic T‑lymphocyte‑associated antigen 4 (CTLA‑4), acting as an immune checkpoint inhibitor to enhance antitumor immunity. By binding specifically to CTLA‑4 receptors on T cells, it blocks inhibitory signals that suppress immune activation, thereby promoting the proliferation and effector function of tumor‑reactive T lymphocytes. Engineered with an optimized immunoglobulin backbone for improved stability and safety, it is commonly developed in combination with PD‑1 inhibitors to achieve synergistic immune activation. As a key component of dual checkpoint combination therapies, tuvonralimab is under clinical evaluation for multiple advanced solid tumors, aiming to overcome immune resistance and improve clinical outcomes in patients with limited treatment options.In 2025, global Tuvonralimab production reached approximately 300,000 vials.
Tuvonralimab targets the advanced solid tumor sector as a dual immune checkpoint combination antibody. Relying on the synergistic blockade mechanism of PD‑1/CTLA‑4 dual targets, it has demonstrated clear clinical value and a solid safety profile in indications such as cervical cancer, making it a representative combination therapy among domestic innovative antibody drugs. Its market development is in the early stage, with core demand driven by unmet medical needs for patients who have failed first‑line treatment or have refractory disease. As clinical research expands to multiple cancer types including liver cancer and lung cancer, it is expected to further broaden the applicable population and prescription scenarios. In terms of competition, the domestic market for similar dual antibodies and immunotherapy combinations is becoming increasingly fierce, and pricing and medical insurance access strategies will significantly affect early penetration. Manufacturers enhance drug accessibility through process optimization and supply chain improvement, while strengthening clinical recognition via academic promotion and real‑world data accumulation, laying a foundation for subsequent market expansion. In the long run, overseas clinical development and international layout will be key to growth, and innovations in combination regimens and biomarker selection will determine its long‑term competitiveness in the complex landscape of cancer treatment.
This report is a detailed and comprehensive analysis for global Tuvonralimab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Tuvonralimab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Tuvonralimab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Tuvonralimab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Tuvonralimab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Tuvonralimab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Tuvonralimab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Qilu Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Tuvonralimab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
50 mg / 2 mL
100 mg / 10 mL
Market segment by Route of Administration
Intravenous Infusion
Intravenous injection
Market segment by Combination Medication
Iparomlimab Combined With Tuvonralimab
Bevacizumab Combination Therapy
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Application
Cervical Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer
Others
Major players covered
Qilu Pharmaceuticals
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Tuvonralimab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Tuvonralimab, with price, sales quantity, revenue, and global market share of Tuvonralimab from 2021 to 2026.
Chapter 3, the Tuvonralimab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Tuvonralimab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Tuvonralimab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Tuvonralimab.
Chapter 14 and 15, to describe Tuvonralimab sales channel, distributors, customers, research findings and conclusion.